INDICATIONS AND USAGE

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors rifapentinerifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

rifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rilzabrutinibrilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with moderate CYP3A inhibitors. rilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavirritonavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dosage of CYP3A4 substrates, if clinically indicated. rucaparib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamiderufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

selpercatinibselpercatinib increases toxicity of vardenafil by QTc interval. selpercatinib increases toxicity of vardenafil by QTc interval.

• Vardenafil is generally safe when used as prescribed.
• The tablet is typically taken around 30 minutes before sex.
• Alcohol may enhance side effects like dizziness.
• Do not use vardenafil if you are taking nitrates.
• Keep a schedule of your medication use.
• Inform your doctor about other medications you are taking.
• Use only prescribed dosage to prevent adverse effects.
• Avoid certain foods that may interfere with absorption.
• Healthcare providers may adjust doses based on response.
• Proper storage extends the shelf life of the medication.

Coadministration cenforce fm 100mg of sepiapterin with drugs affecting nitric oxide-mediated relaxation may cause additive vasodilation and further reduce blood pressure. sertralinesertraline and vardenafil both increase QTc interval. sertraline and vardenafil both increase QTc interval. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.

6.1 Clinical Studies Experience

primaquineprimaquine and vardenafil both increase QTc interval. primaquine and vardenafil both increase QTc interval. primidoneprimidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by QTc interval.

Pregnancy and breastfeeding

Avoid libido for women use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT. quininevardenafil and quinine both increase QTc interval. vardenafil and quinine both increase QTc interval. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs. sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of vardenafil by QTc interval. sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of vardenafil by QTc interval.

solifenacinsolifenacin and vardenafil both increase QTc interval. solifenacin and vardenafil both increase QTc interval. sorafenibsorafenib and vardenafil both increase QTc interval. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects.

• Vardenafil 10 mg is one of several ED treatment options.
• It is generally well-tolerated when used properly.
• Take care to follow your healthcare provider’s instructions.
• Possible interactions with antihypertensive drugs exist.
• Do not drive or operate machinery if feeling dizzy.
• Keep a record of any side effects experienced.
• The medication is not a cure for erectile dysfunction.
• Combining vardenafil with other ED drugs is dangerous.
• Take the tablet with a full glass of water.
• Consult your doctor for dose adjustments if needed.

sunitinibsunitinib and vardenafil both increase QTc interval. sunitinib and vardenafil both increase QTc interval. suzetriginesuzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic indexes when coadministered with suzetrigine. Consider modifying dose of sensitive substrate according to prescribing recommendations. suzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Concomitant use may increase the risk of QTc interval prolongation.

Advancing Effective Research Policy

osimertinib and vardenafil both increase QTc interval. ozanimodozanimod and vardenafil both increase QTc interval. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties. ozanimod and vardenafil both increase QTc interval. vardenafil and pasireotide both increase QTc interval.

Dosage Modifications

pentobarbitalpentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What should I tell my healthcare provider before taking vardenafil?

phenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. posaconazoleposaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if cheapest ed pills coadministered with moderate or strong CYP3A4 inhibitors posaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors prednisoneprednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. prednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If concomitant use is unavoidable, adjust the frequency of ECG and electrolyte monitoring. tecovirimattecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.

Further information

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nelfinavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetronnetupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors netupitant/palonosetron will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors nevirapinenevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

How is vardenafil supplied (dosage forms)?

nifedipinenifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinibnilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/72 hr olanzapineolanzapine and vardenafil both increase QTc interval.

Experts Discuss the Potential Role of GLP-1 Receptor Agonists in Breast Cancer Outcomes and Survivorship Care

olanzapine and vardenafil both increase QTc interval. olodaterol inhaledvardenafil and olodaterol inhaled both increase QTc interval. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias vardenafil and olodaterol inhaled both increase QTc interval. osilodrostat and vardenafil both increase QTc interval. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval. tecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tetracyclinetetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

5.7 Congenital or Acquired QT Prolongation

relacorilantrelacorilant increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with a strong CYP3A4 inhibitor. relacorilant increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec revumenib and vardenafil both increase QTc interval. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec ribociclibribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tobramycin inhaledtobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity tobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity topiramatetopiramate will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.